Milestone Pharmaceuticals Inc. MIST
Set alert
0.74 USD +0.01 +0.88%
As of Nov 2, 12:19 PM ET
0.7233 Day range 0.7799
0.631 52-week range 3.06
- YTD
- -63.54%
- 1 year
- -61.65%
- Open
- 0.77
- Prev close
- 0.73
- Mkt cap
- 91.69M
- Vol
- 255.39K
- Avg vol
- 1.35M
- EPS
- -0.68
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7233
- High
- 0.7799
- Forward P/E
- -2.15
- Beta
- 1.73
- Short ratio
- 2.46
- Inst. own
- 57.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.71
- 200-d avg
- 1.58
- 1y target
- 10.25
1Y chart
Signals (48)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
| RSI: Oversold | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 5 months ago |
| RSI: Oversold | Jun 3, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 6 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| RSI: Overbought | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 7 months ago |
| RSI: Oversold | Mar 26, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 20, 2026 | 7 months ago |
| RSI: Oversold | Mar 20, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 9 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 16, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| SMA: Bearish | Dec 17, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 12, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| RSI: Overbought | Nov 25, 2025 | 11 months ago |
| RSI: Overbought | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 14, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
Key statistics
- Market cap
- 98.66M
- Enterprise value
- 93.76M
- Trailing P/E
- 0.00
- Forward P/E
- -2.15
- PEG ratio
- 0.00
- Price / book
- 4.76
- EPS (TTM)
- -0.80
- Beta
- 1.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -23.84M
- Total cash
- 83.25M
- Total debt
- 53.25M
- Return on equity
- -133.75%
- Shares outstanding
- 53.33M
- Short % of float
- 0.86%
- 50-day average
- 1.71
- 200-day average
- 1.58
Analyst view
Consensus: none
Price target (mean) 10.25 +1291.9% upside
Now 0.7364
- Target (low)
- 2.00
- Target (mean)
- 10.25
- Target (high)
- 25.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.15.
Financials — quick view
MIST Revenue — quarterly 559.00K
MIST Net income — quarterly -28.61M
MIST EPS — quarterly -0.21
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.16 | -0.14 | +0.02 | +12.50% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | -0.14 | +0.05 | +26.32% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.26 | -0.21 | +0.05 | +19.23% |
| May 13, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.30 | -0.32 | -0.02 | -6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | Rodman & Renshaw | init | — | Buy |
| Jul 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- milestonepharma.com
News
- New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
- Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
- Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
- Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Rating of “Moderate Buy” by Brokerages
- HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target
- Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults
- Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
- Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
- Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026
Your note
Sign in to keep a note on MIST — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.32% | 4,971,344 | 9.20M | Sep 29, 2024 |
| RTW Investments LP | 6.11% | 3,256,102 | 6.02M | Sep 29, 2024 |
| Millennium Management Llc | 5.21% | 2,778,525 | 5.14M | Sep 29, 2024 |
| Alta Fundamental Advisers LLC | 4.99% | 2,658,589 | 4.92M | Sep 29, 2024 |
| Citadel Advisors Llc | 3.87% | 2,061,522 | 3.81M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 3.75% | 2,000,000 | 3.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.04% | 19,311 | 35.73K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 17,576 | 32.52K | Oct 30, 2024 |
| JNL Series Trust-JNL/DFA U.S. Small Cap Fund | 0.00% | 1,661 | 3.07K | Sep 29, 2024 |